• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » QED Clinical Services establishes subsidiary in India

QED Clinical Services establishes subsidiary in India

March 22, 2012
CenterWatch Staff

CRO QED Clinical Services has created a wholly owned subsidiary, QED Clinical Services India Private Limited, in Ahmedabad, India, to enhance its global delivery of clinical trials.

The subsidiary adds operational and therapeutic expertise to QED, and expands its capacity and capability to offer more global coverage.

QED operations in India will be spearheaded by country head and director of operations Ali Saijad Bohra, who has led clinical monitoring, FSP models and project management across India, South East Asia, Japan, South Korea and Australia. 

“India and the Asia Pacific region will continue to have focus and will remain key markets for the drug development activities for biopharmaceutical companies on account of a variety of benefits,” said Bohra.

In addition to conducting trials in India, QED India will act as a hub for QED’s Asia Pacific operations for control and oversight of its local partners across the region.

“The creation of QED Clinical, India means that we can better meet the global development needs of our sponsors by giving access to vast patient populations via regional experts on the ground,” said CEO Thomas Ogorka. “India continues to receive great focus as an emerging territory and QED’s presence here means we can leverage its high-quality capabilities.”

 

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing